CJC-1295 Research for Growth Hormone Deficiency
An evidence-based overview of research examining CJC-1295 in the context of growth hormone deficiency. This page synthesizes findings from peer-reviewed literature.
Research Summary
CJC-1295 was developed to address the need for longer-acting GHRH analogs in growth hormone deficiency. Phase 1-2 trials demonstrated sustained elevations in GH and IGF-1 levels with once or twice-weekly dosing. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days and maintaining IGF-1 elevation for 9-11 days after a single injection. This addresses the pharmacokinetic limitations of native GHRH. However, clinical development was discontinued in 2006 after a participant death (deemed unrelated to the drug but due to pre-existing coronary disease). No approved GHRH-based therapies use CJC-1295.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. CJC-1295 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.